LLY Jan 2025 520.000 put
| Previous Close | 9.25 |
| Open | 9.25 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 520.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 9.25 - 9.25 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
- Yahoo Finance Video
Why these analysts are bullish on healthcare stocks
The healthcare sector has underperformed throughout 2024, but as the first quarter earnings season unfolds, Jefferies Healthcare Services Equity Research Analyst Brian Tanquilut and Grey Ghost Advisors Private Equity Investor Meghan Fitzgerald join Market Domination to discuss how investors should position themselves in this market. Fitzgerald remains bullish on the healthcare sector, believing it still has "a lot of long and important tailwinds." She cites the sector's historical outperformance during market downturns and election years as reasons for her optimism. Fitzgerald anticipates strong earnings from companies with GLP-1 drug portfolios this week, describing it as an "easy beat." Tanquilut notes a "rise in broader healthcare utilization trends," which is now reflected in healthcare insurers' earnings. While there has been weakness in this area, he highlights the "strength in volume" from healthcare providers. However, Tanquilut acknowledges that with consumer spending slowing, consumer-focused healthcare segments, such as drugstores, have experienced pressure. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's note: This article was written by Angel Smith
Yahoo FinanceHow expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?
Barrons.comAll Eyes Are on Zepbound Sales as Lilly Reports Earnings
When Eli Lilly the world-beating behemoth of the big pharma market, reports its quarterly results on Tuesday, the question for investors will be how fast sales of its obesity drug are climbing. Lilly shares are up 82% over the past 12 months and 26% so far this year. Investors, and the general public, have been extraordinarily enthusiastic about the company’s weight-loss drug Zepbound, which the company also sells as a treatment for Type 2 diabetes under the name Mounjaro.
